Cost-Effectiveness of Insulin Degludec/Insulin Aspart (IDEGASP) Compared with Biphasic Insulin Aspart (BIASP 30) in Patients with Type 2 Diabetes Mellitus from a Mexican Healthcare Perspective
Abstract
Authors
V Sánchez-Pedraza BB Hansen J Gundgaard J García Uranga Romano M Evans